· Developing strategies for efficient and sequence-specific DNA modifying agents. Site specific cleavage of RNA and DNA will
be sought by developing novel chemical nucleases and PDT-directed cleavage agents, respectively.
· PNA based molecular beacons
· siRNA delivery
· Chemically stabilized siRNA for improved gene silencing.
· Developing site-specific anti-cancer agents to the mitochondria.
Current projects include:
Photo-dynamic therapy based on anti-gene recognition: Developing DNA-dye conjugates for the direct and site-specific photocleavage of DNA.
Chemical nucleases based on a cyclic peptide scaffold.
The synthesis of novel PNA based MB's for early diagnosis of colorectal cancer.
Improved stability and delivery of siRNA for efficient gene regulation.
Anti-cancer agents targeted to mitochondria.
Active collaborations include:
Prof. Israel Ringel on the development of anti-cancer agents targeting the mitochondria.
Prof. Chezy Barenholz on siRNA delivery based on modified peptides.
Profs. Simon Benita and Philip Lazarovici on siRNA delivery based on nano-encapsulated NP's.
Prof. Avri Rubinstein on the development of PNA based molecular beacons.
Prof. Joshua Katzhendler on the development of novel PNA's.